Biotech startups are rapidly developing blood tests claiming to detect multiple cancers early, but these tests have yet to meet the rigorous criteria required for traditional cancer screening. While promising, concerns arise over the influence of commercial interests on the standards of evidence for these tests. Experts argue that these tests must demonstrate a reduction in cancer-specific mortality to be considered reliable, and upcoming trials may be crucial in determining their true effectiveness.
Keep Reading
Add A Comment